Abstract
None of the FDA-approved Alzheimer’s disease (AD) treatments address the main hallmarks of the disease. With the recent clinical trial shortcomings of AD immunotherapy as well as γ- and β-secretase inhibitors among others, we and colleagues agree that a multifactorial approach is needed to address the polygenicity of AD. We used an epigenetic strategy where a single drug would simultaneously affect the expression of well-defined AD-related targets.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
